Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $51.75 Average PT from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have earned a consensus rating of “Buy” from the nine ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $51.75.

Several brokerages recently issued reports on VERA. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a research report on Monday, September 16th.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of Vera Therapeutics stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Vera Therapeutics news, CEO Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Beth C. Seidenberg sold 1,177 shares of Vera Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the transaction, the director now directly owns 160,376 shares of the company’s stock, valued at $6,737,395.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,273 shares of company stock worth $1,210,750. Insiders own 21.70% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently made changes to their positions in the company. Public Employees Retirement Association of Colorado purchased a new position in shares of Vera Therapeutics during the 2nd quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics in the 2nd quarter valued at about $163,000. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares in the last quarter. Cetera Advisors LLC bought a new stake in shares of Vera Therapeutics in the 1st quarter valued at about $235,000. Finally, Quarry LP bought a new stake in shares of Vera Therapeutics in the 2nd quarter valued at about $235,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Trading Up 1.9 %

Shares of NASDAQ VERA opened at $42.78 on Wednesday. The firm’s 50 day moving average price is $37.35 and its 200-day moving average price is $39.11. The company has a market cap of $2.34 billion, a PE ratio of -20.87 and a beta of 0.99. Vera Therapeutics has a 52-week low of $9.24 and a 52-week high of $50.78. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, equities research analysts expect that Vera Therapeutics will post -2.57 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.